Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tobira Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01092104
First received: March 22, 2010
Last updated: July 3, 2013
Last verified: July 2013